0001063537 RiceBran Technologies false --12-31 Q1 2023 5,252,996 8 27 20,000,000 20,000,000 3,000 3,000 150 150 150 150 150 150 0 0 15,000,000 15,000,000 6,384,934 6,384,934 6,309,509 6,309,509 0.1 5 10 3 5 5 15 0.1 9.9 4.8 5.3 4.3 6.3 9.0 11.6 7.8 9.3 2 1.26 00010635372023-01-012023-03-31 xbrli:shares 00010635372023-05-11 thunderdome:item iso4217:USD 00010635372022-01-012022-03-31 iso4217:USDxbrli:shares 00010635372023-03-31 00010635372022-12-31 0001063537ribt:LineOfCreditWithBankMember2023-03-31 0001063537ribt:LineOfCreditWithBankMember2022-12-31 0001063537us-gaap:SeriesGPreferredStockMember2023-03-31 0001063537us-gaap:SeriesGPreferredStockMember2022-12-31 0001063537ribt:FactoringAgreementMember2023-01-012023-03-31 0001063537ribt:FactoringAgreementMember2022-01-012022-03-31 0001063537ribt:LineOfCreditWithBankMember2023-01-012023-03-31 0001063537ribt:LineOfCreditWithBankMember2022-01-012022-03-31 00010635372021-12-31 00010635372022-03-31 xbrli:pure 0001063537ribt:StabilizedRiceBranSRBMember2023-03-31 0001063537ribt:StabilizedRiceBranSRBMemberstpr:CA2023-03-31 0001063537ribt:StabilizedRiceBranSRBMemberribt:LouisianaAndArkansasDeltaRegionMember2023-03-31 0001063537ribt:StabilizedRiceBranSRBMemberribt:ArkansasGoldenRidgeAndMinnesotaMGIMember2023-03-31 0001063537us-gaap:MoneyMarketFundsMember2023-03-31 0001063537us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberribt:CustomerAMember2023-01-012023-03-31 0001063537us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberribt:CustomerBMember2023-01-012023-03-31 0001063537us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberribt:CustomerCMember2023-01-012023-03-31 0001063537us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberribt:CustomerDMember2023-01-012023-03-31 0001063537us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberribt:CustomerEMember2023-01-012023-03-31 0001063537us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberribt:CustomerAMember2022-01-012022-03-31 0001063537us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberribt:CustomerBMember2022-01-012022-03-31 0001063537us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberribt:CustomerCMember2022-01-012022-03-31 0001063537us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberribt:CustomerDMember2022-01-012022-03-31 0001063537us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberribt:CustomerEMember2022-01-012022-03-31 0001063537us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberribt:CustomerAMember2023-01-012023-03-31 0001063537us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberribt:CustomerBMember2023-01-012023-03-31 0001063537us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberribt:CustomerCMember2023-01-012023-03-31 0001063537us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberribt:CustomerDMember2023-01-012023-03-31 0001063537us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberribt:CustomerEMember2023-01-012023-03-31 0001063537us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberribt:CustomerAMember2022-01-012022-12-31 0001063537us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberribt:CustomerBMember2022-01-012022-12-31 0001063537us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberribt:CustomerCMember2022-01-012022-12-31 0001063537us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberribt:CustomerDMember2022-01-012022-12-31 0001063537us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberribt:CustomerEMember2022-01-012022-12-31 0001063537country:US2023-01-012023-03-31 0001063537country:US2022-01-012022-03-31 0001063537ribt:OtherCountriesMember2023-01-012023-03-31 0001063537ribt:OtherCountriesMember2022-01-012022-03-31 0001063537us-gaap:LandMember2023-03-31 0001063537us-gaap:LandMember2022-12-31 0001063537us-gaap:FurnitureAndFixturesMember2023-03-31 0001063537us-gaap:FurnitureAndFixturesMember2022-12-31 utr:Y 0001063537us-gaap:FurnitureAndFixturesMembersrt:MinimumMember2023-03-31 0001063537us-gaap:FurnitureAndFixturesMembersrt:MaximumMember2023-03-31 0001063537ribt:PlantMember2023-03-31 0001063537ribt:PlantMember2022-12-31 0001063537ribt:ComputerAndSoftwareMember2023-03-31 0001063537ribt:ComputerAndSoftwareMember2022-12-31 0001063537ribt:ComputerAndSoftwareMembersrt:MinimumMember2023-03-31 0001063537ribt:ComputerAndSoftwareMembersrt:MaximumMember2023-03-31 0001063537us-gaap:LeaseholdImprovementsMember2023-03-31 0001063537us-gaap:LeaseholdImprovementsMember2022-12-31 0001063537us-gaap:MachineryAndEquipmentMember2023-03-31 0001063537us-gaap:MachineryAndEquipmentMember2022-12-31 0001063537us-gaap:MachineryAndEquipmentMembersrt:MinimumMember2023-03-31 0001063537us-gaap:MachineryAndEquipmentMembersrt:MaximumMember2023-03-31 0001063537ribt:PropertyAndEquipmentMember2023-03-31 0001063537ribt:PropertyAndEquipmentMember2022-12-31 0001063537srt:MinimumMember2023-03-31 0001063537srt:MaximumMember2023-03-31 0001063537ribt:FinanceAgreementsForAnnualInsurancePremiumsMember2023-03-31 0001063537ribt:FactoringAgreementMemberus-gaap:LineOfCreditMember2019-10-31 0001063537ribt:FactoringAgreementMemberus-gaap:LineOfCreditMember2019-01-012019-10-31 0001063537ribt:MortgageAgreementMember2022-09-302022-09-30 0001063537ribt:MortgageAgreementMemberus-gaap:PrimeRateMember2022-09-302022-09-30 0001063537ribt:MortgageAgreementMemberus-gaap:PrimeRateMember2022-12-31 0001063537ribt:MortgageAgreementMemberus-gaap:PrimeRateMember2023-01-31 0001063537ribt:FactoringAgreementMemberus-gaap:LineOfCreditMember2023-03-312023-03-31 0001063537ribt:FactoringAgreementMemberus-gaap:LineOfCreditMember2022-01-012022-03-31 0001063537ribt:MortgageAgreementMember2023-03-31 0001063537ribt:MortgageAgreementMember2022-12-31 0001063537ribt:EquipmentNotesMay2021Memberus-gaap:NotesPayableOtherPayablesMember2023-03-31 0001063537ribt:EquipmentNotesMay2021Memberus-gaap:NotesPayableOtherPayablesMember2022-12-31 0001063537ribt:EquipmentNotesDecember2019Memberus-gaap:NotesPayableOtherPayablesMember2023-03-31 0001063537ribt:EquipmentNotesDecember2019Memberus-gaap:NotesPayableOtherPayablesMember2022-12-31 0001063537ribt:ProgressPaymentAgreementMember2023-03-31 0001063537ribt:ProgressPaymentAgreementMember2022-12-31 0001063537ribt:MortgageAgreementAtModificationMember2023-01-31 0001063537ribt:MortgageAgreementAtModificationMember2023-01-012023-01-31 0001063537ribt:MortgageAgreementMember2023-01-31 0001063537ribt:OverAdvanceNoteMember2023-01-31 0001063537ribt:MortgageAgreementAtModificationMemberus-gaap:PrimeRateMember2023-01-312023-01-31 0001063537us-gaap:SeriesGPreferredStockMemberus-gaap:PreferredStockMember2022-12-31 0001063537us-gaap:CommonStockMember2022-12-31 0001063537us-gaap:PreferredStockMember2022-12-31 0001063537us-gaap:RetainedEarningsMember2022-12-31 0001063537us-gaap:SeriesGPreferredStockMemberus-gaap:PreferredStockMember2023-01-012023-03-31 0001063537us-gaap:CommonStockMember2023-01-012023-03-31 0001063537us-gaap:PreferredStockMember2023-01-012023-03-31 0001063537us-gaap:RetainedEarningsMember2023-01-012023-03-31 0001063537ribt:StockUnitsIssuedSUIMemberus-gaap:SeriesGPreferredStockMemberus-gaap:PreferredStockMember2023-01-012023-03-31 0001063537ribt:StockUnitsIssuedSUIMemberus-gaap:CommonStockMember2023-01-012023-03-31 0001063537ribt:StockUnitsIssuedSUIMemberus-gaap:PreferredStockMember2023-01-012023-03-31 0001063537ribt:StockUnitsIssuedSUIMemberus-gaap:RetainedEarningsMember2023-01-012023-03-31 0001063537ribt:StockUnitsIssuedSUIMember2023-01-012023-03-31 0001063537us-gaap:SeriesGPreferredStockMemberus-gaap:PreferredStockMember2023-03-31 0001063537us-gaap:CommonStockMember2023-03-31 0001063537us-gaap:PreferredStockMember2023-03-31 0001063537us-gaap:RetainedEarningsMember2023-03-31 0001063537us-gaap:SeriesGPreferredStockMemberus-gaap:PreferredStockMember2021-12-31 0001063537us-gaap:CommonStockMember2021-12-31 0001063537us-gaap:PreferredStockMember2021-12-31 0001063537us-gaap:RetainedEarningsMember2021-12-31 0001063537us-gaap:SeriesGPreferredStockMemberus-gaap:PreferredStockMember2022-01-012022-03-31 0001063537us-gaap:CommonStockMember2022-01-012022-03-31 0001063537us-gaap:PreferredStockMember2022-01-012022-03-31 0001063537us-gaap:RetainedEarningsMember2022-01-012022-03-31 0001063537us-gaap:SeriesGPreferredStockMemberus-gaap:PreferredStockMember2022-03-31 0001063537us-gaap:CommonStockMember2022-03-31 0001063537us-gaap:PreferredStockMember2022-03-31 0001063537us-gaap:RetainedEarningsMember2022-03-31 0001063537us-gaap:EmployeeStockOptionMemberribt:The2014EquityIncentivePlanMember2023-01-012023-03-31 0001063537us-gaap:RestrictedStockUnitsRSUMemberribt:The2014EquityIncentivePlanMember2023-01-012023-03-31 0001063537ribt:The2014EquityIncentivePlanMember2023-01-012023-03-31 0001063537us-gaap:RestrictedStockUnitsRSUMember2022-12-31 0001063537us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-12-31 0001063537ribt:StockUnitsIssuedSUIMember2022-12-31 0001063537ribt:StockUnitsIssuedSUIMember2022-01-012022-12-31 0001063537us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-03-31 0001063537us-gaap:RestrictedStockUnitsRSUMember2023-03-31 0001063537ribt:StockUnitsIssuedSUIMember2023-03-31 0001063537us-gaap:RestrictedStockUnitsRSUMember2021-01-012021-12-31 0001063537ribt:StockUnitsIssuedSUIMember2021-01-012021-12-31 0001063537us-gaap:RestrictedStockUnitsRSUMember2021-12-31 0001063537ribt:StockUnitsIssuedSUIMember2021-12-31 0001063537ribt:DeferredRestrictedStockUnitsRsusMember2023-03-31 0001063537us-gaap:RestrictedStockUnitsRSUMemberus-gaap:SubsequentEventMemberribt:FormerChiefFinancialOfficerMember2023-04-012023-04-30 0001063537us-gaap:RestrictedStockUnitsRSUMemberus-gaap:SubsequentEventMemberribt:FormerChiefFinancialOfficerMember2023-04-30 0001063537us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-03-31 0001063537us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-03-31 0001063537us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-03-31 0001063537us-gaap:FairValueMeasurementsRecurringMember2023-03-31 0001063537us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-31 0001063537us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-31 0001063537us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-31 0001063537us-gaap:FairValueMeasurementsRecurringMember2022-12-31 0001063537ribt:WarrantAMemberus-gaap:DerivativeFinancialInstrumentsLiabilitiesMember2021-09-13 0001063537ribt:WarrantAMemberus-gaap:DerivativeFinancialInstrumentsLiabilitiesMember2022-09-30 0001063537ribt:WarrantAMemberus-gaap:DerivativeFinancialInstrumentsLiabilitiesMember2021-09-132021-09-13 0001063537ribt:WarrantAMemberus-gaap:DerivativeFinancialInstrumentsLiabilitiesMember2023-03-31 0001063537us-gaap:MeasurementInputExercisePriceMember2023-03-31 0001063537us-gaap:MeasurementInputExercisePriceMember2022-12-31 0001063537us-gaap:MeasurementInputPriceVolatilityMember2023-03-31 0001063537us-gaap:MeasurementInputPriceVolatilityMember2022-12-31 0001063537us-gaap:MeasurementInputRiskFreeInterestRateMember2023-03-31 0001063537us-gaap:MeasurementInputRiskFreeInterestRateMember2022-12-31 0001063537us-gaap:MeasurementInputExpectedTermMember2023-03-31 0001063537us-gaap:MeasurementInputExpectedTermMember2022-12-31 0001063537us-gaap:MeasurementInputExpectedDividendRateMember2023-03-31 0001063537us-gaap:MeasurementInputExpectedDividendRateMember2022-12-31 0001063537us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MeasurementInputExercisePriceMember2023-01-012023-03-31 00010635372023-01-312023-01-31 0001063537us-gaap:OtherIncomeMember2023-01-012023-03-31
 

 

Table of Contents

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

         


FORM 10-Q

 

QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended March 31, 2023

 

TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from __________ to __________

 

Commission File Number 001-36245

RiceBran Technologies

(Exact Name of Registrant as Specified in its Charter)

 

California

(State or other jurisdiction of

incorporation or organization)

87-0673375

(I.R.S. Employer Identification No.)

25420 Kuykendahl Rd., Suite B300

Tomball, TX

 (Address of Principal Executive Offices) 

77375

(Zip Code)

(281) 675-2421

(Registrant’s telephone number, including area code)

 

None

(Former name, former address and former fiscal year, if changed since last report)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading symbol

 

Name of each exchange on which registered

Common Stock, no par value per share

 

RIBT

 

The NASDAQ Capital Market

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company, or an emerging company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ☐Accelerated filer ☐Non-accelerated filerSmaller reporting company
   Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule l2b-2 of the Exchange Act). Yes  No  ☒

 

As of May 11, 2023, there were 6,392,434 shares of common stock outstanding.

 

 

 

 

RiceBran Technologies

Index

Form 10-Q

 

PART I. FINANCIAL INFORMATION

Page

 

Item 1.

Financial Statements (Unaudited)

2

 

 

Condensed Consolidated Statements of Operations for the Three Months Ended March 31, 2023 and 2022

3
   

Condensed Consolidated Balance Sheets as of March 31, 2023, and December 31, 2022

4
   

Condensed Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2023 and 2022

5
   

Notes to Unaudited Condensed Consolidated Financial Statements

6

 

Item 2.

Managements Discussion and Analysis of Financial Condition and Results of Operations

15

 

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

16

 

Item 4.

Controls and Procedures

16

PART II. OTHER INFORMATION

16

 

Item 1.

Legal Proceedings

16

 

Item 1A.

Risk Factors

16

 

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

16

 

Item 3.

Defaults Upon Senior Securities

16

 

Item 4.

Mine Safety Disclosures

16

 

Item 5.

Other Information

16

 

Item 6.

Exhibits

17

Signatures

18

 

 

Cautionary Note about Forward-Looking Statements

 

This quarterly report on Form 10-Q contains “forward-looking statements” concerning our operations, economic performance and financial condition. All statements other than statements of historical fact are “forward-looking statements” for purposes of federal and state securities laws, including, but not limited to, any projections of earnings, revenue, liquidity or other financial items; any statements of the plans, strategies and objectives of management for future operations; any statements concerning proposed new services, products or developments; any statements regarding future economic conditions or performance; any statements of belief; and any statements of assumptions underlying any of the foregoing. Forward-looking statements may include the words “may,” “could,” “will,” “estimate,” “intend,” “continue,” “believe,” “expect” or “anticipate” or other similar words. The forward-looking statements contained herein reflect our current views with respect to future events and are subject to certain risks, uncertainties and assumptions. Actual results may differ materially from those projected in such forward-looking statements due to a number of factors, risks and uncertainties, including the factors that may affect future results set forth in this Quarterly Report on Form 10-Q and in our Annual Report on Form 10-K for the year ended December 31, 2022. Forward-looking statements speak only as of the date on which they are made, and we disclaim any obligation to update any forward-looking statements as a result of developments occurring after the date of this quarterly report.

 

Unless the context requires otherwise, references to “we,” “us,” “our” and “the Company” refer to RiceBran Technologies and its consolidated subsidiaries.

 

 

PART I. FINANCIAL INFORMATION

 

Item 1. Financial Statements.

 

 

2

 

 

RiceBran Technologies

Condensed Consolidated Statements of Operations

(Unaudited) (in thousands, except share and per share amounts)

 

   

Three Months Ended March 31,

 
   

2023

   

2022

 
                 

Revenues

  $ 9,269     $ 10,559  

Cost of goods sold

    9,551       10,057  

Gross profit (loss)

    (282 )     502  

Selling, general and administrative expenses

    1,731       1,692  

Operating loss

    (2,013 )     (1,190 )

Other income (expense):

               

Interest income

    19       1  

Interest expense

    (196 )     (126 )

Change in fair value of derivative warrant liability

    (28 )     (171 )

Other expense

    (60 )     (34 )

Other income

    256       4  

Loss before income taxes

    (2,022 )     (1,516 )

Income tax expense

    (6 )     -  

Net loss

  $ (2,028 )   $ (1,516 )
                 

Loss per common share:

               

Basic

  $ (0.31 )   $ (0.29 )

Diluted

  $ (0.31 )   $ (0.29 )
                 

Weighted average number of shares outstanding:

               

Basic

    6,567,978       5,252,996  

Diluted

    6,567,978       5,252,996  

 

See Notes to Unaudited Condensed Consolidated Financial Statements

 

3

 

 

RiceBran Technologies

Condensed Consolidated Balance Sheets

(Unaudited) (in thousands, except share amounts)

 

  

March 31,

  

December 31,

 
  

2023

  

2022

 
         

Current assets:

        

Cash and cash equivalents

 $3,412  $3,941 

Accounts receivable, net of allowance for credit losses of $8 and $27

  3,337   3,703 

Inventories

  2,562   2,378 

Other current assets

  989   1,046 

Total current assets

  10,300   11,068 

Property and equipment, net

  14,214   14,207 

Operating lease right-of-use assets

  1,686   1,778 

Intangible assets

  351   380 

Total assets

 $26,551  $27,433 
         

LIABILITIES AND SHAREHOLDERS' EQUITY

        

Current liabilities:

        

Accounts payable

 $1,869  $1,232 

Commodities payable

  1,818   1,546 

Accrued salary, wages and benefits

  926   696 

Accrued legal

  625   595 

Accrued expenses

  333   529 

Operating lease liabilities, current portion

  364   391 

Due under bank line of credit

  1,868   1,832 

Due under factoring agreement

  2,801   3,150 

Due under insurance premium finance agreements

  207   185 

Finance lease liabilities, current portion

  160   125 

Long-term debt, current portion

  1,192   996 

Total current liabilities

  12,163   11,277 

Operating lease liabilities, less current portion

  1,430   1,557 

Finance lease liabilities, less current portion

  504   325 

Long-term debt, less current portion

  1,152   1,296 

Derivative warrant liability

  97   69 

Total liabilities

  15,346   14,524 

Commitments and contingencies

          

Shareholders' equity:

        

Preferred stock, 20,000,000 shares authorized:

        

Series G, convertible, 3,000 shares authorized, stated value $150,

  75   75 

150 shares, issued and outstanding

        

Common stock, no par value, 15,000,000 shares authorized,

        

6,384,934 shares and 6,309,509 shares, issued and outstanding

  328,875   328,551 

Accumulated deficit

  (317,745)  (315,717)

Total shareholders' equity

  11,205   12,909 

Total liabilities and shareholders' equity

 $26,551  $27,433 

 

See Notes to Unaudited Condensed Consolidated Financial Statements

 

4

 

 

RiceBran Technologies

Condensed Consolidated Statements of Cash Flows

(Unaudited) (in thousands)

 

   

Three Months Ended March 31,

 
   

2023

   

2022

 

Cash flow from operating activities:

               

Net loss

  $ (2,028 )   $ (1,516 )

Adjustments to reconcile net loss to net cash provided by (used in) operating activities

               

Depreciation

    517       516  

Amortization

    29       43  

Stock and share-based compensation

    324       246  

Change in fair value of derivative warrant liability

    28       171  

Other

    (78 )     (48 )

Changes in operating assets and liabilities:

               

Accounts receivable

    385       (493 )

Inventories

    (184 )     (39 )

Accounts payable and accrued liabilities

    616       884  

Commodities payable

    272       589  

Other

    57       (163 )

Net cash provided by (used in) operating activities

    (62 )     190  

Cash flows from investing activities:

               

Purchases of property and equipment

    (230 )     (157 )

Proceeds from insurance on involuntary conversion

    -       109  

Net cash used in investing activities

    (230 )     (48 )

Cash flows from financing activities:

               

Advances on factoring agreement

    8,559       8,856  

Payments on factoring agreement

    (8,908 )     (8,797 )

Advances of bankline of credit

    36       -  

Advances on insurance premium finance agreements

    206       374  

Payments on insurance premium finance agreements

    (184 )     (219 )

Proceeds from debt, net of issuance costs

    2,494       -  

Payments of debt and finance lease liabilities

    (2,440 )     (313 )

Net cash used in financing activities

    (237 )     (99 )

Net change in cash and cash equivalents

  $ (529 )   $ 43  
                 

Cash and cash equivalents, beginning of period

    3,941       5,825  

Cash and cash equivalents, end of period

    3,412       5,868  

Net change in cash and cash equivalents

  $ (529 )   $ 43  
                 

Supplemental disclosures:

               

Cash paid for interest

  $ 193     $ 118  

Cash paid for income taxes

  $ 1     $ -  

 

See Notes to Unaudited Condensed Consolidated Financial Statements

 

5

 
 
RiceBran Technologies
Notes to Unaudited Condensed Consolidated Financial Statements
 

NOTE 1. BASIS OF PRESENTATION

 

In the opinion of management, the accompanying unaudited condensed consolidated financial statements (interim financial statements) of RiceBran Technologies and its subsidiaries were prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) and the rules and regulations of the Securities and Exchange Commission (the SEC) for reporting on Form 10-Q; therefore, they do not include all of the information and notes required by GAAP for complete financial statements. The interim financial statements contain all adjustments necessary to present fairly the interim results of operations, financial position and cash flows for the periods presented of a normal and recurring nature necessary to present fairly the interim results of operations, financial position and cash flows for the periods presented.

 

These interim financial statements should be read in conjunction with the consolidated audited financial statements and notes thereto in our Annual Report on Form 10-K for the year ended December 31, 2022, which included all disclosures required by generally accepted accounting principles.

 

The results reported in these interim financial statements are not necessarily indicative of the results to be expected for the full fiscal year, or any other future period, and have been prepared based on the realization of assets and the satisfaction of liabilities in the normal course of business. 

 

Certain reclassifications have been made to amounts reported for the prior year to achieve consistent presentation with the current year. Such reclassifications had no impact on previously reported net loss or shareholders’ equity.

 

NOTE 2. BUSINESS

 

We are a specialty ingredient company focused on the development, production, and marketing of products derived from traditional and ancient small grains. We create and produce products utilizing proprietary processes to deliver improved nutrition, ease of use, and extended shelf-life, while addressing consumer demand for all natural, non-GMO and organic products.

 

Notably, we convert raw rice bran into stabilized rice bran (SRB), and high value-added derivative products including: RiBalance, a rice bran nutritional package derived from SRB; RiSolubles, a nutritious, carbohydrate and lipid rich fraction of RiBalance; RiFiber, a fiber rich insoluble derivative of RiBalance and ProRyza, a rice bran protein-based product.

 

SRB is an additive used in human and animal foods. SRB has certain attractions compared to additives based on the by-products of other agricultural commodities, such as corn, soybeans, wheat, and yeast. Our SRB and SRB derivatives are healthy, natural, hypoallergenic, gluten free, and non-genetically modified ingredients used in a variety of applications.

 

We produce SRB from four locations: two facilities located within supplier-owned rice mills in California; and two company-owned facilities in Louisiana and the Arkansas delta region. We produce SRB derivatives at our Dillon, Montana, facility and we operate two specialty milling facilities, a rice mill in Arkansas, Golden Ridge, and a barley and oats mill in Minnesota, MGI.

 

Segment Reporting

 

Given the integrated nature of the products we produce and the facilities in which we produce them, we have one reporting unit and one operating segment, as defined in applicable accounting guidance, specialty ingredients.

 

NOTE 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Recent accounting standards not yet adopted

 

There are no accounting standard(s) not yet adopted that will, or are expected to, result in a significant change in practice and/or have a significant financial impact on our financial position, results of operations or cash flows.

 

6

RiceBran Technologies
Notes to Unaudited Condensed Consolidated Financial Statements
 

Recently adopted accounting standards.

 

In June 2016, the Financial Accounting Standards Board issued guidance ASU No. 2016-13 Financial InstrumentsCredit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments which changes the accounting for credit losses for certain instruments, including trade receivables, from an incurred loss method to a current expected loss method. The measurement of expected credit losses is based on relevant information about past events, including historical experience, current conditions, and reasonable and supportable forecasts. We adopted the guidance, and subsequent guidance related to the topic, effective January 1, 2023. Adoption of the standard had no significant impact on our results of operations, financial position, or cash flows as of January 1, 2023. Our provision for doubtful accounts, recoveries of doubtful accounts and accounts receivable charge-offs were immaterial in all periods presented.

 

NOTE 4. CASH AND CASH EQUIVALENTS

 

As of March 31, 2023, we have $2.7 million of cash and cash equivalents invested in a money market fund with net assets invested in U.S. Dollar denominated money market securities of domestic and foreign issuers, U.S. Government securities and repurchase agreements. We consider all liquid investments with original maturities of three months or less at the time of purchase to be cash equivalents.

 

We have cash on deposit in excess of federally insured limits at a bank. We do not believe that maintaining substantially all such assets with the bank or investing in a liquid mutual fund represent material risks.

 

 

NOTE 5. ACCOUNTS RECEIVABLE AND REVENUES

 

Revenues in the three months ended March 31, 2023 and 2022, include $0.1 million, or less, in unearned revenue as of the end of the prior year.

 

Our accounts receivable potentially subject us to significant concentrations of credit risk. Revenues and accounts receivable from significant customers (customers with revenue or accounts receivable in excess of 10% of consolidated totals) are stated below as a percent of consolidated totals.

 

  

Customer

 
  

A

  

B

  

C

  

D

  

E

 

% of revenue, three months ended March 31, 2023

  17%  10%  7%  3%  2%

% of revenue, three months ended March 31, 2022

  -%  11%  5%  2%  11%
                     

% of accounts receivable, as of March 31, 2023

  -%  22%  10%  12%  1%

% of accounts receivable, as of December 31, 2022

  19%  12%  4%  9%  -%

 

The following table presents revenues by geographic area shipped to (in thousands).

 

  

Three Months Ended March 31,

 
  

2023

  

2022

 

United States

 $8,947  $10,246 

Other countries

  322   313 

Revenues

 $9,269  $10,559 
 

NOTE 6. INVENTORIES

 

The following table details the components of inventories (in thousands).

 

   

March 31,

   

December 31,

 
   

2023

   

2022

 

Finished goods

  $ 1,937     $ 1,737  

Raw materials

    386       423  

Packaging

    239       218  

Inventories

  $ 2,562     $ 2,378  

 

7

RiceBran Technologies
Notes to Unaudited Condensed Consolidated Financial Statements
 
 

NOTE 7. PROPERTY AND EQUIPMENT

 

The following table details the components of property and equipment (amounts in thousands).

 

  

March 31,

  

December 31,

  
  

2023

  

2022

 

Estimated Useful Lives (years)

Land

 $730  $730  

Furniture and fixtures

  259   259 

5-10 

Plant

  10,095   10,095 

20-40, or life of lease

Computer and software

  450   450 

3-5 

Leasehold improvements

  1,838   1,838 

4-15, or life of lease

Machinery and equipment

  16,227   15,703 

5-15 

Property and equipment, cost

  29,599   29,075  

Less accumulated depreciation

  15,385   14,868  

Property and equipment, net

 $14,214  $14,207  

 

Amounts payable for property and equipment included in accounts payable and accrued liabilities totaled $0.1 million at March 31, 2023, and December 31, 2022. Assets which had not yet been placed in service, included in property and equipment, totaled $1.7 million at March 31, 2023, and $1.2 million at December 31, 2022.

 

 

NOTE 8. LEASES

 

The components of lease expense and cash flows from leases (in thousands) follow.

 

   

Three Months Ended March 31,

 
   

2023

   

2022

 

Finance lease cost:

               

Amortization of right-of use assets, included in cost of goods sold

  $ 15     $ 20  

Interest on lease liabilities

    18       2  

Operating lease cost, included in selling, general and administrative expenses:

               

Fixed lease cost

    129       129  

Variable lease cost

    51       46  

Short-term lease cost

    43       7  

Total lease cost

  $ 256     $ 204  
                 

Cash paid for amounts included in the measurement of lease liabilities:

               

Operating cash flows from finance leases

  $ 18     $ 2  

Operating cash flows from operating leases

  $ 129     $ 129  

Financing cash flows from finance leases

  $ 36     $ 24  

 

As of March 31, 2023, variable lease payments do not depend on a rate or index. As of March 31, 2023, property and equipment, net, includes $0.6 million of finance lease right-of-use-assets, with an original cost of $1.1 million. As of December 31, 2022, property and equipment, net, includes $0.2 million of finance lease right-of-use-assets, with an original cost of $0.9 million. During the three months ended March 31, 2023, we financed the purchase of $0.2 million of property and equipment in noncash finance lease transactions. During the three months ended March 31, 2022, we financed the purchase of less than $0.1 million of property and equipment in noncash finance lease transactions.

 

As of March 31, 2023, we do not believe it is certain that we will exercise any renewal options. The remaining terms of our leases and the discount rates used in the calculation of our lease liabilities as of March 31, 2023, follows.

 

   

Operating

Leases

 

Finance

Leases

Remaining leases terms (in years)

  0.6 -  9.9   0.1 -  4.8

Weighted average remaining lease terms (in years)

    5.3       4.3  

Discount rates

   6.3% - 9.0%   2.8% - 11.6%

Weighted average discount rate

    7.8%       9.3 %

 

Maturities of lease liabilities as of March 31, 2023, follow (in thousands).

 

   

Operating

   

Finance

 
   

Leases

   

Leases

 

2023 (nine months ended December 31, 2023)

  $ 337     $ 180  

2024

    429       182  

2025

    439       167  

2026

    451       164  

2027

    232       125  

Thereafter

    346       3  

Total lease payments

    2,234       821  

Amounts representing interest

    (440 )     (157 )

Present value of lease obligations

  $ 1,794     $ 664  

 

8

RiceBran Technologies
Notes to Unaudited Condensed Consolidated Financial Statements
 
 

NOTE 9. DEBT

 

We finance certain amounts owed for annual insurance premiums under financing agreements. As of March 31, 2023, amounts due under insurance premium financing agreements are due in monthly installments of principal and interest through November 30, 2023, at an interest rate of 7.3% per year.

 

We borrow under a factoring agreement with a lender (the Lender), which provides a $7.0 million credit facility. We may only borrow to the extent we have qualifying accounts receivable to use as collateral as defined in the agreement. The facility had an initial two-year term and automatically renews for successive annual periods until delivery of a proper termination notice. The facility term automatically extended to October 2023. We incur recurring fees under the agreement, including a funding fee of 0.5% above the prime rate, in no event to be less than 5.5%, on any advances, and a service fee on average net funds borrowed. The Lender has a security interest in our assets and the right to demand repayment of the advances at any time.

 

The Lender also advanced us $0.9 million effective September 30, 2022 (the Over-advance), pending restructuring of our mortgage promissory note with the Lender. The Over-advance accrued interest at an annual rate which was the greater of 7.0% above the Lender's prime rate (14.5% at December 31, 2022) and 10.3% until it was repaid in January 2023. As of December 31, 2022, the Over-advance was classified as long-term debt in our consolidated balance sheet as it was refinanced on a long-term basis in January 2023, as discussed below.

 

Additional information related to our factoring obligation (exclusive of the Over-advance) follows.

 

    Three Months Ended March 31,  
   

2023

   

2022

 

Average borrowings outstanding (in thousands)

  $ 2,771     $ 2,822  

Amortization of debt issuance costs (in thousands)

  $ -     $ 23  

Fees paid, as a percentage of average oustanding borrowings

    2.2 %     1.2 %

Interest paid, as a percentage of average outstanding borrowings

    2.2 %     1.5 %

 

9

RiceBran Technologies
Notes to Unaudited Condensed Consolidated Financial Statements
 

As of  March 31, 2023, we had $1.9 million outstanding under a line of credit with a bank. The borrowing was secured by our cash on deposit with the bank and bears interest at prime (7.8% at  March 31, 2023). There were no stipulated repayment terms for the line as long as we maintained sufficient cash collateral. We repaid the amounts borrowed under the line of credit in full in April 2023. Our borrowings under the line of credit averaged $1.8 million in the three months ended  March 31, 2023, at an average annual interest rate of 7.7%.

 

Long-term debt consists of the following (in thousands).

 

   

March 31,

   

December 31,

 
   

2023

   

2022

 

Mortgage promissory note - Originally dated July 2020 and modified in January 2023. As modified, interest accrues at an annual rate which is the greater of 7.0% above the Lender's prime rate (15.0% at March 31, 2023) and 10.3%. Payable in monthly installments through January 2025. Face amount $2.5 million. Secured by certain real property in Wynne, Arkansas.

  $ 2,306     $ 2,211  

Equipment note - Dated May 2021. Original principal $46. Due in monthly installments through June 2025. Interest accrues at the effective discount rate of 3.6% per year.

    22       24  

Equipment note - Dated December 2019. Original principal $40. Due in monthly installments through December 2024. Interest accrues at the effective discount rate of 9.3% per year.

    16       18  

Progress payment agreement - Dated August 2022. Original principal $37. Interest was payable monthly at the rate of 25.2% per year until obligation was transferred to a finance lease in February 2023.

    -       39  

Total long-term debt, net

  $ 2,344     $ 2,292  

 

In January 2023, we entered into agreements with the Lender to effect a modification of the terms of the mortgage promissory note. This modification involved us entering into a new mortgage promissory note in the principal amount of $2.5 million. We received $0.3 million in cash and the Lender applied the remainder of the new principal to the $1.3 million then outstanding on the prior mortgage promissory note and the $0.9 million Over-advance. Under the terms of the January 2023 note, (i) interest accrues at the same rate as the prior note, an annual rate which is the greater of 7.0% above the 1ender’s prime rate and 10.3%, and (ii) principal and interest are payable in equal monthly installments through January 2025. Prior to the modification, principal and interest were payable in equal monthly installments through December 2023. The new note is secured by a mortgage on our real property in Arkansas. The current portion of long-term debt on the consolidated balance sheet as of December 31, 2022, reflects the terms of the January 2023 modification.

 

Future principal maturities of long-term debt outstanding as of  March 31, 2023, follow (in thousands).

 

2023 (nine months ended December 31, 2023)

  $ 886  

2024

    1,346  

2025

    124  

Principal maturities

    2,356  

Debt issuance costs

    (12 )

Total long term debt, net

  $ 2,344  
 

NOTE 10. EQUITY, SHARE-BASED COMPENSATION AND WARRANTS

 

A summary of equity activity for the three months ended March 31, 2023 and 2022, follows (in thousands, except share amounts).

 

   

Shares

                                 
   

Preferred

           

Preferred

   

Common

   

Accumulated

         
   

Series G

   

Common

   

Stock

   

Stock

   

Deficit

   

Equity

 

Balance, December 31, 2022

    150       6,309,509     $ 75     $ 328,551     $ (315,717 )   $ 12,909  

Common stock awards under equity incentive plans

    -       68,693       -       300       -       300  

Stock units issued to vendor

    -       6,132       -       23       -       23  

Common stock issued to vendor

    -       600       -       1       -       1  

Net loss

    -       -       -       -       (2,028 )     (2,028 )

Balance, March 31, 2023

    150       6,384,934     $ 75     $ 328,875     $ (317,745 )   $ 11,205  

 

 

   

Shares

                                 
   

Preferred

           

Preferred

   

Common

   

Accumulated

         
   

Series G

   

Common

   

Stock

   

Stock

   

Deficit

   

Equity

 

Balance, December 31, 2021

    150       5,158,967     $ 75     $ 326,279     $ (307,859 )   $ 18,495  

Common stock awards under equity incentive plans

    -       22,475       -       241       -       241  

Common stock issued to vendor

    -       600       -       5       -       5  

Net loss

    -       -       -       -       (1,516 )     (1,516 )

Balance, March 31, 2022

    150       5,182,042     $ 75     $ 326,525     $ (309,375 )   $ 17,225  

 

10

RiceBran Technologies
Notes to Unaudited Condensed Consolidated Financial Statements
 

Share-based compensation by type of award for the three months ended March 31, 2023, follows (in thousands).

 

Stock options

  $ 27  

Restricted stock units

    273  

Compensation expense related to common stock awards issued under equity incentive plan

  $ 300  

 

 

We have outstanding (i) restricted stock units issued under the 2014 Plan (RSUs) to employees and directors and (ii) other restricted stock units held by a service provider (SUs). Each RSU and SU represents a contingent right to receive one share of common stock. Summaries of nonvested and vested restricted stock unit activity follow.

 

  

RSUs

  

SUs

 
  

Number of

Units

  

Unrecognized Compensation

(in thousands)

  

Average

Grant Date

Fair Value

per share

  

Weighted

Average

Expense

Period

(Years)

  

Numer of

Units

  

Unrecognized Compensation

(in thousands)

  

Average

Grant Date

Fair Value

per share

  

Weighted

Average

Expense

Period

(Years)

 

Nonvested at December 31, 2022

  366,818  $1,024  $2.79   2.8   160,000  $201  $1.26  $3 

Granted

  76,088   70   0.93   -   6,132   5   0.74   - 

Forfeited

  (646)  (3)  4.64   0.6   -   -   -   - 

Vested with service

  (164,781)  -       -   (6,132)  -   -   - 

Expensed

  -   (274) 

NA

   -   -   (24)  -   - 

Nonvested at March 31, 2023

  277,479  $817  $2.94   2.6   160,000  $182  $-   2.5 

 

 

  

Number of RSUs

 

Vested at December 31, 2022

  224,725 

Vested with service

  170,913 

Issued at vesting

  (74,825)

Vested at March 31, 2023

  320,813 

 

As of March 31, 2023, issuance of 466,603 shares of common stock subject to certain RSUs, 320,813 of which are vested, is deferred to the date the holder is no longer providing service to RiceBran Technologies.

 

In April 2023, 89,143 RSUs were forfeited upon the resignation of our former chief financial officer, resulting in a $0.3 million reduction in unrecognized compensation.

 

11

RiceBran Technologies
Notes to Unaudited Condensed Consolidated Financial Statements
 
 

NOTE 11. INCOME TAXES

 

Our tax expense for the three months ended  March 31, 2023 and 2022, differs from the tax expense computed by applying the U.S. statutory tax rate to loss before income taxes as no tax benefits were recorded for tax losses generated in the U.S. As of March 31, 2023, we had deferred tax assets primarily related to U.S. federal and state tax loss carryforwards. We provided a full valuation allowance against our deferred tax assets as future realization of such assets is not more likely than not to occur.

 

NOTE 12. LOSS PER SHARE (EPS)

 

We calculate basic EPS under the two-class method under which all earnings (distributed and undistributed) are allocated to each class of common stock and participating securities based on their respective rights to receive dividends. Our outstanding convertible preferred stock are considered participating securities as the holders may participate in undistributed earnings with holders of common shares and are not obligated to share in our net losses.

 

We calculate diluted EPS by dividing the net income attributable to RiceBran Technologies common shareholders by the weighted average number of common shares outstanding during the period increased by the number of additional common shares that would have been outstanding if the impact of assumed exercises and conversions is dilutive. We calculate the dilutive effects of outstanding options, warrants and nonvested restricted stock units that vest solely on the basis of a service condition using the treasury stock method. We calculate the dilutive effects of outstanding preferred stock using the if-converted method.

 

Reconciliations of the numerators and denominators in the EPS computations follow.

 

   

Three Months Ended March 31,

 
   

2023

   

2022

 

NUMERATOR (in thousands):

               

Basic and diluted - net loss

  $ (2,028 )   $ (1,516 )
                 

DENOMINATOR:

               

Weighted average number of shares of shares of common stock outstanding

    6,337,031       5,166,491  

Weighted average number of shares of common stock underlying vested restricted stock units

    230,947       86,505  

Basic and diluted EPS - weighted average number of shares outstanding

    6,567,978       5,252,996  

 

No effects of potentially dilutive securities outstanding were included in the calculation of diluted EPS for the three months ended March 31, 2023 and 2022, because to do so would be antidilutive as a result of our net loss. Potentially dilutive securities outstanding at March 31, 2023, included our outstanding convertible preferred stock, options, warrants and nonvested restricted stock units.

 

NOTE 13. FAIR VALUE MEASUREMENTS

 

The fair value of cash and cash equivalents, accounts receivable, accounts payable. commodities payable and short-term debt approximates their carrying value due to shorter maturities. As of March 31, 2023, the fair value of our operating lease liabilities was approximately $0.3 million lower than their carrying values, based on current market rates for similar debt and leases with similar maturities (Level 3 measurements), and the fair values of our long-term debt and finance lease liabilities approximated their carrying values, based on current market rates for similar debt and leases with similar maturities (Level 3 measurements).

 

12

RiceBran Technologies
Notes to Unaudited Condensed Consolidated Financial Statements
 

The following tables summarize the fair values by input hierarchy of items measured at fair value on a recurring basis on our consolidated balance sheets (in thousands):

 

   

Level 1

   

Level 2

   

Level 3

   

Total

 
                                 

Total liabilities at fair value as of March 31, 2023 - Derivative warrant liability

  $ -     $ -     $ 97     $ 97  

Total liabilities at fair value as of December 31, 2022 - Derivative warrant liability

  $ -     $ -     $ 69     $ 69  

 

The following tables summarize the changes in level 3 items measured at fair value on a recurring basis for the three months ended March 31, 2023, (in thousands):

 

   

Fair Value as

of Beginning

of Period

   

Total
Realized and

Unrealized
Gains
(Losses)

   

Issuance of

New

Instruments

   

Net
Transfers
(Into) Out of
Level 3

   

Fair Value, at

End of Period

   

Change in

Unrealized

Gains

(Losses) on

Instruments Still Held

 

Three Months Ended March 31, 2023:

                                               

Derivative warrant liability

  $ 69     $ (28 )   $ -     $ -     $ 97     $ (28 )

Total Level 3 fair value

  $ 69     $ (28 )   $ -     $ -     $ 97     $ (28 )
                                                 

Three Months Ended March 31, 2022:

                                               

Derivative warrant liability

  $ 258     $ (171 )   $ -     $ -     $ 429     $ (171 )

Total Level 3 fair value

  $ 258     $ (171 )   $ -     $ -     $ 429     $ (171 )

 

The derivative warrant liability relates to a warrant issued in September 2021 for the purchase of up to 230,769 shares of common stock (Warrant A), The current $2.72 per share exercise price of Warrant A is subject to adjustment in September 2023 to 110% of the 5-day volume weighted average price of our common stock if that price is less than $2.72 per share. We classify Warrant A in our consolidated balance sheets as derivative warrant liability because the holder may elect cash settlement of this warrant in the event of a change of control. We estimated the fair value of Warrant A as of March 31, 2023, and December 31, 2022, using the Black-Scholes value of a warrant with an exercise price of $2.72 per share. The changes in the estimated fair value of Warrant A are included in other income (loss) in our consolidated statements of operations. The assumptions used in valuing Warrant A follow.

 

   

March 31, 2023

   

December 31, 2022

 

Assumed exercise price

  $ 2.72     $ 2.72  

Assumed volatility

    96.8 %     92.2 %

Assumed risk free interest rate

    4.2 %     4.3 %

Expected life of options (in years)

    3.5       3.7  

Expected dividends

    -       -  

 

The fair value of Warrant A approximates the cash settlement the holder could elect to be paid in the event of a change in control. At March 31, 2023, a $0.10 increase in our stock price would have resulted in approximately a $15 thousand increase in the Black Scholes fair value of Warrant A.

 

 

 

 

13

RiceBran Technologies
Notes to Unaudited Condensed Consolidated Financial Statements

NOTE 14. COMMITMENTS AND CONTINGENCIES

 

Employment Contracts and Severance Payments

 

In the normal course of business, we periodically enter into employment agreements which incorporate indemnification provisions. While the maximum amount to which we may be exposed under such agreements cannot be reasonably estimated, we maintain insurance coverage, which we believe will effectively mitigate our obligations under these indemnification provisions. No amounts have been recorded in our financial statements with respect to any obligations under such agreements.

 

We have employment contracts with certain officers and key management that include provisions for potential severance payments in the event of without-cause terminations or terminations under certain circumstances after a change in control. In addition, vesting of outstanding nonvested equity grants would accelerate following a change in control.

 

Legal Matters

 

From time to time, we are involved in litigation incidental to the conduct of our business. These matters may relate to employment and labor claims, patent and intellectual property claims, claims of alleged non-compliance with contract provisions and claims related to alleged violations of laws and regulations. When applicable, we record accruals for contingencies when it is probable that a liability will be incurred and the amount of loss can be reasonably estimated. While the outcome of lawsuits and other proceedings against us cannot be predicted with certainty, in the opinion of management, individually or in the aggregate, no such lawsuits are expected to have a material effect on our financial position or results of operations. We expense defense as incurred. Defense costs, when incurred, are included in selling, general and administrative expense.

 

In  January 2023, we received $0.3 million in restitution payments from a former employee. The payments were ordered by a federal court in 2012. Other income in the three months ended March 31, 2023, includes a $0.3 million gain as a result of collecting the restitution payment.

 

14

RiceBran Technologies
Notes to Unaudited Condensed Consolidated Financial Statements
 

 

 

Item 2. Managements Discussion and Analysis of Financial Condition and Results of Operations

 

Results of Operations

 

Revenues of $9.3 million in the first quarter of 2023 decreased $1.3 million, or 12.2%, compared to the first quarter of 2022. This year-over-year net decrease included a decrease in value-added derivative SRB revenues and a decrease in MGI milling revenues, offset by an increase in Golden Ridge milling revenues. Lower value-added derivative SRB revenues were largely the result of increased competition following a new market entrant. MGI milling revenues declined due to the final completion and integration of its capital expansion project in the first quarter of 2023.

 

Gross loss was $0.3 million in the first quarter of 2023, compared to a gross profit of $0.5 million in the first quarter of 2022. The $0.8 million decrease in gross profit was primarily due to the impact of the year-over-year decline in value-added derivative SRB revenues.

 

Selling, general and administrative expenses were $1.7 million in the first quarter of 2023, consistent with the first quarter of 2022.

 

Operating losses were $2.0 million in the first quarter of 2023, up from $1.2 million in the first quarter of 2022, due to the decrease in gross profits discussed above.

 

Other income (expense), net, decreased $0.3 million from the first quarter of 2022 to the first quarter of 2023 primarily due to the receipt of $0.3 million in restitution payments from a former employee, which had been ordered by a federal court in 2012.

 

As a result of higher operating losses being offset by lower other expense, net, net loss in the first quarter of 2023 was $2.0 million, or $0.31 per share, compared to $1.5 million, or $0.29 per share, in the first quarter of 2022.

 

Liquidity, Going Concern and Capital Resources

 

We had $3.4 million in cash and equivalents as of March 31, 2023, a decline of $0.5 million from December 31, 2022. Cash used in operating activities in 2023 was $0.1 million in the first quarter of 2023 compared to cash provided by operations of $0.2 million in 2022, driven by the $0.5 million increase in net losses offset by the $0.3 million restitution payment received in the first quarter of 2023. Cash used in investing activities in 2022 was $0.2 million, which consisted of capital expenditures. Cash used in financing activities in 2023 was $0.2 million, which included a $0.3 million reduction in borrowing on our factoring.

 

Management believes that despite the multi-year history of operating losses and negative operating cash flows from continuing operations, there is no substantial doubt about our ability to continue as a going concern within one year after the date that these financial statements included in this Quarterly Report are issued. Factors alleviating this concern include our available cash and cash equivalents as of March 31, 2023, expected improvement in profitability of our milling business, and our ability to procure additional capital if needed through a variety of sources, most notably through the disposition, or borrowing against, one of our owned facilities.

 

On March 30, 2020, we entered into a sales agreement with respect to an at-the-market (ATM) offering program, under which we may offer and sell shares of our common stock having an aggregate offering price of up to $6.0 million, which we currently have $2.8 million remaining. Under the terms of the securities purchase agreement related to a September 2021 offering, we are prohibited from entering into an agreement to effect any at-the-market issuance until September 13, 2023. Under the terms of the securities purchase agreement related to the October 2022 offerings, we are generally prohibited from entering into an agreement to effect an offering of our common stock or common stock equivalents until May 20, 2023, or a variable rate transaction, as defined in the agreement, until October 20, 2023.

 

Critical Accounting Estimates

 

Our discussion and analysis of our financial condition and results of operations are based upon unaudited condensed consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of financial statements requires management to make estimates and judgments that affect the reported amounts of assets and liabilities, revenues and expenses and disclosures on the date of the financial statements. On an ongoing basis, we evaluate the estimates, including, but not limited to, those related to revenue recognition, inventory valuation, and long-lived asset impairment. We use authoritative pronouncements, historical experience and other assumptions as the basis for making judgments. Actual results could differ from those estimates.

 

Recent Accounting Pronouncements

 

See Note 3 in the Notes to Unaudited Condensed Consolidated Financial Statements for further discussion.

 

15

 

Item 3. Quantitative and Qualitative Disclosures about Market Risk

 

We are a smaller reporting company as defined in Rule 12b-2 of the Securities Exchange Act of 1934, as amended (the Exchange Act) and are not required to provide the information otherwise required by this item.

 

Item 4. Controls and Procedures

 

Evaluation of Disclosure Controls and Procedures

 

We maintain disclosure controls and procedures, as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, that are designed to provide reasonable assurance that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required financial disclosures. As of March 31, 2023, there have been no significant changes to our critical accounting policies and related estimates previously disclosed in our 2022 Annual Report on Form 10-K.

 

We evaluated, with the participation of our executive chairman, and interim chief financial officer, the effectiveness of our disclosure controls and procedures as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on this evaluation, our executive chairman and interim chief financial officer concluded that our disclosure controls and procedures were effective as of the end of the period covered by this report.

 

Changes in Internal Control over Financial Reporting

 

During the most recently completed fiscal quarter, there have been no changes in our internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

PART II. OTHER INFORMATION

 

Item 1. Legal Proceedings

 

We are involved in or subject to, or may become involved in or subject to, routine litigation, claims, disputes, proceedings and investigations in the ordinary course of business. While the outcome of lawsuits and other proceedings against us cannot be predicted with certainty, in the opinion of management, individually or in the aggregate, no such lawsuits are expected to have a material effect on our financial position, results of operations or cash flows. We record accruals for contingencies when it is probable that a liability will be incurred and the amount of loss can be reasonably estimated.

 

Item 1A. Risk Factors

 

In addition to the other information set forth in this Quarterly Report, you should carefully consider the factors discussed in Part I, “Item 1A. Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2022, which could materially affect our business, financial condition, liquidity or future results. The risks described in our Annual Report on Form 10-K are not the only risks facing our company. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition, liquidity or future results.

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

 

During the quarter ended March 31, 2023, we issued the securities described below without registration under the Securities Act of 1933, as amended. The description below does not include issuances that we disclosed previously on Current Reports on Form 8-K. Unless otherwise indicated below, the securities were issued pursuant to the private placement exemption provided by Section 4(a)(2) of the Securities Act of 1933, as amended. All issuances below were made without any public solicitation, to a limited number of sophisticated persons and were acquired for investment purposes only.

 

On March 31, 2023, we issued 600 shares of common stock to a service provider, that is not a natural person, as compensation for service provided. The shares were valued at an aggregate of $444.

 

On March 2, 2023, we issued 6,132 shares of common stock to a service provider, that is not a natural person, upon vesting of stock units that were purchased by the service provider using the performance-based compensation for services that was earned by the service provider pursuant to a performance compensation agreement. The shares were valued at an aggregate of $4,568.

 

Item 3. Defaults upon Senior Securities

 

None

 

Item 4. Mine Safety Disclosures

 

None

 

Item 5. Other Information

 

None

 

16

 

Item 6. Exhibits

 

The following exhibits are attached hereto and filed herewith:

 

       

Incorporated by Reference

   

Exhibit

Number

 

Exhibit Description

 

Form

 

File No.

 

Exhibit

Number

 

Filing/Effective

Date

 

Filed

Here-with

10.1

 

Mortgage Agreement and Amendment for Purchase and Sale with Republic Business Credit, LLC

 

8-K

 

001-36245

 

10.18

 

January 19, 2023

   

31.1

 

Certification by Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

                 

X

31.2

 

Certification by Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

                 

X

32.1

 

Certification by Principal Executive Officer and Principal Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

                 

X

101.INS (1)

 

Inline XBRL Instance Document

                 

X

101.SCH (1)

 

Inline XBRL Taxonomy Extension Schema Document

                 

X

101.CAL (1)

 

Inline XBRL Taxonomy Extension Calculation Linkbase Document

                 

X

101.DEF (1)

 

Inline XBRL Taxonomy Extension Calculation Definition Linkbase Document

                 

X

101.LAB (1)

 

Inline XBRL Taxonomy Extension Calculation Label Linkbase Document

                 

X

101.PRE (1)

 

Inline XBRL Taxonomy Extension Calculation Presentation Linkbase Document

                 

X

104

 

Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

                   

 

 

(1)

XBRL (Extensible Business Reporting Language) information is furnished and not filed or a part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise is not subject to liability under these sections.

 

17

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

Dated:  May 11, 2023

   
     
 

/s/ Peter G. Bradley

 
 

Peter G. Bradley

 

Director and Executive Chairman

     
  /s/ William J. Keneally  
  William J. Keneally  
  Interim Chief Financial Officer

 

18